Sandoz Looks To Biosimilars As It Reprioritizes In The US

US Sandoz President Carol Lynch Talks Changing Portfolio

Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.

Carol Lynch, Sandoz US
Sandoz US President Carol Lynch • Source: Sandoz

Sandoz is shrinking the size of its US footprint as it prioritizes complex generics and biosimilars in the region and divests much of its small molecule generics portfolio to India's Aurobindo. US President Carol Lynch talked about the changing dynamics for the US business and the company's positive outlook for biosimilars in an interview with Generics Bulletin sister publication Scrip at the BIO CEO & Investor conference in New York on 10 February.

"We are looking forward to closing the transaction and when that's behind us, then obviously we've got a smaller business...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business